.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,316,029

« Back to Dashboard

Details for Patent: 6,316,029

Title: Rapidly disintegrating solid oral dosage form
Abstract:Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.
Inventor(s): Jain; Rajeev A. (Norristown, PA), Ruddy; Stephen B. (Schwenksville, PA), Cumming; Kenneth Iain (Phibsoboro, GB), Clancy; Maurice Joseph Anthony (Dublin, IE), Codd; Janet Elizabeth (Athlone, IE)
Assignee: Flak Pharma International, Ltd. (Shannon, IL)
Filing Date:May 18, 2000
Application Number:09/572,961
Claims:1. An oral solid dose rapidly disintegrating nanoparticulate formulation comprising:

(a) a solid dose matrix comprising at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, and

(b) within the solid dose matrix a nanoparticulate active agent composition comprising:

(i) a poorly soluble active agent having an effective average particle size of less than about 2000 nm prior to inclusion in the dosage form; and

(ii) at least one surface stabilizer adsorbed on the surface of the active agent;

wherein the solid dose matrix surrounding the nanoparticulate active agent and at least one surface stabilizer substantially completely disintegrates or dissolves upon contact with saliva is less than about 3 minutes.

2. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 1500 nm.

3. The composition of claim 1, wherein the solid dose matrix substantially completely disintegrates or dissolves upon contact with saliva in a time period selected from the group consisting of less than about 2 minutes, less than about 90 seconds, less than about 60 seconds, less than about 45 seconds, less than about 30 seconds, less than about 20 seconds, less than about 15 seconds, less than about 10 seconds, and less than about 5 seconds.

4. The composition of claim 1, wherein the concentration of the active agent is from about 0.1% to about 99.9% (w/w).

5. The composition of claim 4, wherein the concentration of the active agent is from about 5% to about 70% (w/w).

6. The composition of claim 5, wherein the concentration of the active agent is from about 15% to about 40% (w/w).

7. The composition of claim 1, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 99.9% to about 0.1% (w/w).

8. The composition of claim 7, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 95% to about 30% (w/w).

9. The composition of claim 8, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 85% to about 60% (w/w).

10. The composition of claim 1, wherein said at least one pharmaceutically acceptable water-soluble or water-dispersible excipient is selected from the group consisting of a sugar, a sugar alcohol, a starch, a natural gum, a natural polymer, a synthetic derivative of a natural polymer, a synthetic polymer, and mixtures thereof.

11. The composition of claim 10, wherein said at least one pharmaceutically acceptable water-soluble or water-dispersible excipient is selected from the group consisting of lactose, glucose, mannose, mannitol, sorbitol, xylitol, erythritol, lactitol, maltitol, corn starch, potato starch, maize starch, gelatin, carrageenin, acacia, xanthan gum, an alginate, dextran, maltodextran, polyethylene glycol, polyvinylpyrrolidone, polyvinylalcohol, polyoxyethylene copolymers, polyoxypropylene copolymers, polyethyleneoxide, and a mixture thereof.

12. The composition of claim 10, wherein said excipient is selected from the group consisting of a direct compression material and a non-direct compression material.

13. The composition of claim 12, wherein said excipient is selected from the group consisting of a spray-dried mannitol and spray-dried lactose.

14. The composition of claim 1, wherein the solid dose formulation is made by fluid bed granulation.

15. The composition of claim 1 further comprising at least one effervescent agent.

16. The composition of claim 1, wherein said composition has been lyophilized.

17. The composition of claim 1, wherein the poorly soluble active agent is in the form of crystalline particles, semi-crystalline particles, amorphous particles, or a mixture thereof.

18. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 1000 nm.

19. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 600 nm.

20. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 400 nm.

21. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 300 nm.

22. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 250 nm.

23. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 100 nm.

24. The composition of claim 1, wherein the effective average particle size of the active agent particles is less than about 50 nm.

25. A method of preparing an oral solid dose rapidly disintegrating nanoparticulate formulation comprising:

(a) combining (i) a nanoparticulate composition of a poorly soluble active agent and at least one surface stabilizer adsorbed to the surface thereof, wherein the active agent has an effective average particle size of less than about 2000 nm, and (ii) at least one pharmaceutically acceptable water-dispersible or water-soluble excipient, which forms a solid dose matrix surrounding the nanoparticulate composition; and

(b) forming a solid dose formulation, wherein the solid dose matrix surrounding the nanoparticulate active agent and surface stabilizer substantially completely disintegrates or dissolves upon contact with saliva in less than about 3 minutes.

26. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 1500 nm.

27. The method of claim 25, wherein the solid dose matrix substantially completely disintegrates or dissolves upon contact with saliva in a time period selected from the group consisting of less than about 2 minutes, less than about 90 seconds, less than about 60 seconds, less than about 45 seconds, less than about 30 seconds, less than about 20 seconds, less than about 15 seconds, less than about 10 seconds, and less than about 5 seconds.

28. The method of claim 25, wherein the nanoparticulate composition and the at least one water-dispersible or pharmaceutically acceptable water-soluble excipient are combined in step (a) using fluid bed granulation to form granules of the nanoparticulate composition and at least one water-soluble or water-dispersible excipient, which are then compressed in step (b) to form a solid dose formulation.

29. The method of claim 28, comprising adding additional pharmaceutically acceptable water-soluble or water-dispersible excipient to the granules formed by fluid bed granulation in step (a) prior to compression of the granules in step (b) to form a solid dose formulation.

30. The method of claim 25 wherein step (b) comprises compression of the composition formed in step (a).

31. The method of claim 25 wherein step (b) comprises lyophilization of the composition formed in step (a).

32. The method of claim 25 additionally comprising adding at least one effervescent agent to the composition prior to step (b).

33. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 1000 nm.

34. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 600 nm.

35. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 400 nm.

36. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 300 nm.

37. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 250 nm.

38. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 100 nm.

39. The method of claim 25, wherein the effective average particle size of the active agent particles is less than about 50 nm.

40. The method of claim 25, wherein the concentration of the active agent is from about 0.1% to about 99.9% (w/w).

41. The method of claim 40, wherein the concentration of the active agent is from about 5% to about 70% (w/w).

42. The method of claim 41, wherein the concentration of the active agent is from about 15% to about 40% (w/w).

43. The method of claim 25, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 99.9% to about 0.1% (w/w).

44. The method of claim 43, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 95% to about 30% (w/w).

45. The method of claim 44, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 85% to about 60% (w/w).

46. The method of claim 25, wherein said at least one pharmaceutically acceptable water-soluble or water-dispersible excipient is selected from the group consisting of a sugar, a sugar alcohol, a starch, a natural gum, a natural polymer, a synthetic derivative of a natural polymer, a synthetic polymer, and mixtures thereof.

47. The method of claim 46, wherein said at least one pharmaceutically acceptable water-soluble or water-dispersible excipient is selected from the group consisting of lactose, glucose, mannose, mannitol, sorbitol, xylitol, erythritol, lactitol, maltitol, corn starch, potato starch, maize starch, gelatin, carrageenin, acacia, xanthan gum, an alginate, dextran, maltodextran, polyethylene glycol, polyvinylpyrrolidone, polyvinylalcohol, polyoxyethylene copolymers, polyoxypropylene copolymers, polyethyleneoxide, and a mixture thereof.

48. The method of claim 46, wherein said excipient is selected from the group consisting of a direct compression material and a non-direct compression material.

49. The method of claim 48, wherein said excipient is selected from the group consisting of a spray-dried mannitol and spray-dried lactose.

50. The method of claim 25, wherein the poorly soluble active agent is in the form of crystalline particles, semi-crystalline particles, amorphous particles, or a mixture thereof.

51. A method of treating a mammal comprising administering to the mammal an effective amount of a solid dose rapidly disintegrating nanoparticulate formulation wherein:

(a) the formulation comprises a solid dose matrix comprising at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, and

(b) within the solid dose matrix a nanoparticulate active agent composition comprising:

(i) a poorly soluble active agent having an effective average particle size of less than about 2000 nm prior to inclusion in the dosage form; and

(ii) at least one surface stabilizer adsorbed on the surface of the active agent;

wherein the solid dose matrix surrounding the nanoparticulate active agent and surface stabilizer substantially completely disintegrates or dissolves upon contact with saliva in less than about 3 minutes.

52. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 1500 nm.

53. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 1000 nm.

54. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 600 nm.

55. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 400 nm.

56. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 300 nm.

57. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 250 nm.

58. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 100 nm.

59. The method of claim 51, wherein the effective average particle size of the active agent particles is less than about 50 nm.

60. The method of claim 51, wherein the concentration of the active agent is from about 0.1% to about 99.9% (w/w).

61. The method of claim 60, wherein the concentration of the active agent is from about 5% to about 70% (w/w).

62. The method of claim 61, wherein the concentration of the active agent is from about 15% to about 40% (w/w).

63. The method of claim 51, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 99.9% to about 0.1% (w/w).

64. The method of claim 63, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 95% to about 30% (w/w).

65. The method of claim 64, wherein the concentration of the pharmaceutically acceptable water-soluble or water-dispersible excipient is from about 85% to about 60% (w/w).

66. The method of claim 51, wherein said at least one pharmaceutically acceptable water-soluble or water-dispersible excipient is selected from the group consisting of a sugar, a sugar alcohol, a starch, a natural gum, a natural polymer, a synthetic derivative of a natural polymer, a synthetic polymer, and mixtures thereof.

67. The method of claim 66, wherein said at least one pharmaceutically acceptable water-soluble or water-dispersible excipient is selected from the group consisting of lactose, glucose, mannose, mannitol, sorbitol, xylitol, erythritol, lactitol, maltitol, corn starch, potato starch, maize starch, gelatin, carrageenin, acacia, xanthan gum, an alginate, dextran, maltodextran, polyethylene glycol, polyvinylpyrrolidone, polyvinylalcohol, polyoxyethylene copolymers, polyoxypropylene copolymers, polyethyleneoxide, and a mixture thereof.

68. The method of claim 66, wherein said excipient is selected from the group consisting of a direct compression material and a non-direct compression material.

69. The method of claim 68, wherein said excipient is selected from the group consisting of a spray-dried mannitol and spray-dried lactose.

70. The method of claim 51, wherein the poorly soluble active agent is in the form of crystalline particles, semi-crystalline particles, amorphous particles, or a mixture thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc